Form 4: Immunic CEO Daniel Vitt Acquires 14,000 Shares of Common Stock

Immunic's CEO, Daniel Vitt, purchased 14,000 shares of the company's common stock at $1.3095 per share on February 26, 2024.

Summary

• On February 26, 2024, Daniel Vitt, the President and CEO of Immunic, Inc., acquired 14,000 shares of Immunic's common stock.
• The purchase price was $1.3095 per share.
• Following the transaction, Mr. Vitt directly owns 14,000 shares and indirectly owns 362,877 shares through Listrax UG, where he serves as Managing Director.
• His spouse also acquired 14,000 shares on the same date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive signal, but the filing itself is a routine disclosure.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and 10% owners) buy or sell their company's stock. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The CEO's stock purchase may positively influence shareholder sentiment.

Key Dates